Human Microbiome Market Analysis

Product (Probiotics, Prebiotics, Diagnostic Tests, Drugs)

The probiotics segment is set to gain the largest market share of 40% by the year 2036. The increasing prevalence of digestive diseases across the globe is driving the demand for probiotics as some probiotics can improve the immune system, reduce inflammation, and may even lower cholesterol. According to statistics, more than 35% of people around the world experience persistent digestive issues. It is assessed that live bacteria and yeasts called probiotics are beneficial to health, particularly the digestive system, and have been proven to be successful in treating common symptoms, including bloating, stomach pain, and diarrhea.

The drugs segment is counted to pool in the highest revenue in the given period owing to the rising investment in the field of live biotherapeutics which is envisaged to develop pharmacologic treatments for a range of diseases.

Disease Type (Infectious Disease, Obesity, Diabetes, Gastrointestinal Diseases, Cancer, Cardiovascular Diseases)

The gastrointestinal diseases segment is speculated to garner a significant growth rate of around 46% through 2036, as the development and treatment of gastrointestinal illnesses are significantly influenced by the human microbiome. Gut health could be improved and the risk of gastrointestinal disorders could be decreased with probiotics, prebiotics, and other microbiome-targeted medicines. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.

Our in-depth analysis of the global market includes the following segments:

Product	Probiotics Prebiotics Diagnostic Tests Drugs
Disease Type	Infectious Disease Obesity Diabetes Gastrointestinal Diseases Cancer Cardiovascular Diseases
Organism Type	Aerobic Organisms Obligate & Facultative Anaerobes Genetically Engineered Strains BSL-2 & Spore-Forming Species
Application	Therapeutics Diagnostics
Technology	Genomics Proteomics Metabolomics

Frequently Asked Questions (FAQ)

Growing prevalence of the human microbiome in health and disease and increasing research on its major impact on human physiology, metabolic and immune functions are the major factors driving the market growth.

The market size of the human microbiome is anticipated to attain a CAGR of 25% over the forecast period, i.e., 2023-2035.

The major players in the market are Seres Therapeutics, Inc., Evelo Biosciences, Inc., Synlogic, Inc., Second Genome Inc., Synthetic Biologics, Inc., YSOPIA Bioscience, 4D pharma plc, DuPont de Nemours, Inc., BiomX Inc., Sun Genomics, Inc., Viome Life Sciences, Inc.

The probiotics segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

Human Microbiome Market Analysis